• Product NamePim-1 (Phospho-Tyr309) Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
• ApplicationsWB
• Species ReactivityHu Ms Rt
• SpecificityThe antibody detects endogenous levels of Pim-1 only when phosphorylated at tyrosine 309.
• Immunogen TypePeptide-KLH
• Immunogen DescriptionPeptide sequence around phosphorylation site of tyrosine 309(H-R-Y(p)-H-G) derived from Human Pim-1.
• Target NamePim-1
• ModificationPhospho
• Alternative Names    PIM-1; Proto-oncogene serine/threonine-protein kinase pim-1; EC 2.7.11.1;
• Accession No. Swiss-Prot#: P11309;
  NCBI Gene#: 5292;
  NCBI Protein#: NP_001230115.1
• UniprotP11309
• Gene ID5292;
• SDS-PAGE MW 45kd
• Concentration 1.0mg/ml
• Formulation Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Storage Store at -20˚C/1 year

• Western blotting: 1:500~1:1000

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis.

Selten G., Cell 46:603-611(1986).
Saris C.J., EMBO J. 10:655-664(1991).
Maita H., Eur. J. Biochem. 267:5168-5178(2000).

• Western blot analysis of extracts from HUVEC cells treated with PMA using Pim-1 (Phospho-Tyr309) Antibody #11677.The lane on the right is treated with the antigen-specific peptide.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting